MediWound (NASDAQ:MDWD) Stock Price Passes Above 50-Day Moving Average – What’s Next?

Shares of MediWound Ltd. (NASDAQ:MDWD) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $17.16 and traded as high as $18.09. MediWound shares last traded at $17.85, with a volume of 80,509 shares traded.

Analyst Ratings Changes

MDWD has been the topic of a number of research reports. Wall Street Zen downgraded shares of MediWound from a “hold” rating to a “strong sell” rating in a report on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a research report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, MediWound has an average rating of “Hold” and a consensus price target of $31.67.

MediWound Trading Up 0.5%

The company’s fifty day moving average is $17.16 and its 200-day moving average is $17.80. The firm has a market capitalization of $229.37 million, a P/E ratio of -8.50 and a beta of 0.15.

MediWound (NASDAQ:MDWD) last announced its earnings results on Saturday, February 14th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter. MediWound had a negative net margin of 140.80% and a negative return on equity of 65.79%. The business had revenue of $1.87 million for the quarter. On average, equities research analysts anticipate that MediWound Ltd. will post -2.66 EPS for the current year.

Institutional Trading of MediWound

A number of hedge funds have recently bought and sold shares of MDWD. Rosalind Advisors Inc. boosted its holdings in MediWound by 84.0% in the 3rd quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock valued at $13,498,000 after purchasing an additional 341,993 shares during the period. Kotler Kevin bought a new stake in shares of MediWound in the 4th quarter worth approximately $6,225,000. Meitav Investment House Ltd. lifted its position in shares of MediWound by 825.7% in the 3rd quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock worth $5,241,000 after acquiring an additional 260,116 shares during the period. Millennium Management LLC lifted its position in shares of MediWound by 355.6% in the 3rd quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock worth $3,160,000 after acquiring an additional 136,884 shares during the period. Finally, UBS Group AG lifted its position in shares of MediWound by 90.1% in the 4th quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company’s stock worth $2,678,000 after acquiring an additional 68,756 shares during the period. 46.83% of the stock is owned by institutional investors.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.